диссертации / 2
.pdf151
108. Lee S., Solow-Cordero D.E., Kessler E. et al. Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C- proteinase and related proteins in fibrogenic cells and keratinocytes. J Biol Chem 1997; 272: 19059–19066.
109.Lehmann E.D., Gosling R.G., Sönksen P.H. Arterial wall compliance in diabetes. Diabet Med. 1992;9:114–119.
110.Levy B.I., Poitevin P., Duriez M. et al. Sodium, survival, and the mechanical properties of the carotid artery in stroke-prone hypertensive rats. J Hypertens. 1997; 15: 251–258.
111.Limas C., Westrum B., Limas C.J. et al. Effect of salt on the vascular lesions of spontaneously hypertensive rats. Hypertension. 1980; 2: 477–489.
112.Liu Y.P., Thijs L., Kuznetsova T. et al. Central Systolic Augmentation Indexes and Urinary Sodium in a White Population. Am J Hypertens. 2013;26 (1): 95-103.
113.Lombardi D., Gordon K.L., Polinsky P. et al. Salt-sensitive hypertension develops after short-term exposure to angiotensin II. Hypertension. 1999;
33:1013–1019.
114.London G.M., Blacher J., Pannier B. et al. Arterial wave reflections and survival in end-stage renal failure . Hypertension . 2001;38:434–438.
115.Loon N.R., Wilcox C.S., Unwin R.J. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney International. 1989;36(4):682–689.
116.López B., González A., Beaumont J. et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–867.
117.López B., González A., Hermida N. et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney International.
.2008;74: 19–23.
|
152 |
118. |
López B., Querejeta R., González A. et al. Effects of loop diuretics |
on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004; 43: 2028–2035.
119.Luft F.C, Grim C.E., Fineberg N., Weinberger M.C. Effects of volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation1979;59:643-650.
120.MacGregor G, de Wardenerb He. Salt, blood pressure and health. Int. J. Epidemiol. 2002;31 (2): 320-327.
121.Magri P., Rao M.A., Cangianiello S. et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonism. Circulation. 1998;98 (25):2849–2854.
122.Mahmud A., Feely J. Spurious systolic hypertension of youth: fit young men with elastic arteries . Am J Hypertens. 2003;16:229–232.
123.Mamenko M., Zaika O., Ilatovskaya D.V. et al. Angiotensin II Increases Activity of the Epithelial Na+ Channel (ENaC) in Distal Nephron Additively to Aldosterone. J Biol Chem. 2012; 2, 287(1): 660–671.
124.Mattace-Raso F., Hofman A., Verwoert G.C. et al. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’ Eur Heart J. 2010; 31 (19): 23382350
125.McEniery C.M., Yasmin, Hall I.R. et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the AngloCardiff Collaborative Trial (ACCT). J Am Coll Cardiol 2005;46:1753-1760.
126.Mervaala E., Dehmel B., Gross V. et al. Angiotensin-Converting Enzyme Inhibition and AT1 Receptor Blockade Modify the Pressure-Natriuresis Relationship by Additive Mechanisms in Rats with Human Renin and Angiotensinogen Genes. ASN. 1999; 10 (8): 1669-1680.
127.Midgley J.P., Matthew A.G., Greenwood C.M. et al. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA. 1996;275:1590-1597.
|
153 |
128. |
Mohanlal V., Parsa A., Weir M.R. Role of dietary therapies in the |
prevention and treatment of hypertension. Nature Reviews Nephrology. 2012; 15,8(7):413-22.
129.Morimoto A., Uzu T., Fujii T. et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet.1997; 350: 1734– 1737.
130.Munkhaugen J., Lydersen S., Widerшe T.E. et al. Prehypertension, obesity, and risk of kidney disease: 20-year follow-up of the HUNT I study in Norway. Am. J. Kidney Dis. 2009; 54(4): 638–646.
131.Mutig K., Kahl T., Saritas T. et al. Activation of the Bumetanide-
sensitive− CotransporterN +,K+,2Cl(NKCC2) Is Facilitated by Tamm |
-Horsfall |
Protein in a Chloride-sensitive Manner. TheJournalofBiologicalChemistry. 2011;
286(34):30200-10.
132.National Research Council. Committee on Diet and Health. Food and Nutrition Board. Commission on Life Sciences. Diet and health: implications for reducing chronic disease risk. Washington, DC: National Academy Press. 1989.
133.Nichols W.W., O’Rourke M.F.; Arnold E. McDonald’s Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 3rd ed. London, UK: Arnold; 1990: 77–142, 216–269, 283–359, 398–437.
134.Nichols W.W., O'Rourke M.F. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles . 5th ed.. London, England: Hodder Arnold; 2005.
135.Nilsson P.M., Boutouyrie P., Laurent S. Vascular Aging. A Tale of EVA and ADAM in Cardiovascular Risk Assessment and Prevention. Hypertension. 2009; 54: 3-10.
136.Nilsson P.M., Lurbe E., Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome [review]. J Hypertens. 2008; 26(6):1049-57.
154
137. |
Nurnberger |
J., Keflioglu-Scheiber A., Opazo Saez A.M. |
et al. Augmentation index is associated with cardiovascular risk . J Hypertens. 2002;20
(12):2407–2414.
138.O’Rourke M.F., Staessen J.A., Vlachopoulos C. et al. Clinical Applications of Arterial Stiffness; Definitions and Reference Values. Am J Hypertens. 2002; 15: 426–444.
139.O’Shaughnessy K.M., Karet F.E. Salt handling and hypertension. J Clin Invest. 2004; 113: 1075–1081.
140.Oberleithner H. A physiological concept unmasking vascular salt sensitivity in man. European Journal of Physiology. 2012; 287-293.
141.Oberleithner H. Two barriers for sodium in vascular endothelium? Ann Med. 2012; 44(1): 143-8.
142.Oberleithner H., Peters W., Kusche-Vihrog K. et al. Salt overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch. 2011; 462:519–528.
143.Oberleithner H., Riethmuller C., Schillers H. et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA. 2007;104:16281–16286.
144.Oliver W.J, Cohen E.L, Neel J.V. Blood pressure, sodium intake and sodium related hormones in Yanomamo Indians, a ‘no-salt’ culture.Circulation.1975;52:146–51.
145.O'Rourke M., Vlachopoulos C., Graham R.M. Spurious systolic hypertension in youth. Vasc Med. 2000; 5:141–5.
146.O'Rourke M.F., Seward J.B. Central Arterial Pressure and Arterial Pressure Pulse: New Views Entering the Second Century After Korotkov. Mayo Clinic Proceedings. 2006;81(8): 1057-1068.
147.Page L.B. Damon A., Moellering R.C. Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation 1974; 49:1132-46.
155
148. Park J.B., Schiffrin blood pressure elevation and vascular Hypertension. 2001; 37: 1444–1449.
E.L. ET(A) receptor antagonist prevents remodeling in aldosterone-infused rats.
149.Park S., Park J..B, Lakatta E.G. Association of central hemodynamics with estimated 24-h urinary sodium in patients with hypertension. J Hypertens. 2011; 29: 1502–9.
150.Partovian C., Benetos A., Pommies J.P. et al. Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin. Am J Physiol. 1998; 274: 1423–1428.
151.Pauca A.L., Kon N.D., O'Rourke M.F. The second peak of the radial artery pressure wave represents aortic systolic pressure in hypertensive and elderly patients . Br J Anaesth. 2004;92:651–657.
152.Pauca A.L., Wallenhaupt S.T., Kon N.D. et al. Does radial artery pressure accurately reflect aortic pressure? Chest. 1992; 102:1193–8.
153.Paul M., Mehr A.P., Kreutz R. Physiology of localrenin-angiotensin systems. Physiol Rev. 2006;86: 747-803.
154.Peixoto A.J., Orias M., Desir G.V. Does Kidney Disease Cause Hypertension?. Current Hypertension Reports. 2013; 15(2): 89-94.
155.Pradervand S., Wang Q., Burnier M. et al. A mouse model for Liddle's syndrome. J Am Soc Nephrol. 1999;10(12):2527-33.
156.Preobrazhenski D.V., Nekrasova N.I., Khoseva E.N. at. el. Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension. Kardiologiia. 2011;51(4):67-73.
157.Pries A.R., Secomb T.W., Gaehtgens P. The endothelial surface layer. Pflugers Arch. 2000;440:653–666.
158.Redelinghuys M., Norton G.R. Scott L. et al. Relationship between urinary salt excretion and pulse pressure and central aortic hemodynamics independent of steady state pressure in the general population. Hypertension. 2010 ; 56 : 584 –590.
159.Reyes A.J. Effects of diuretics on renal excretory function, Eur Heart
J. 1992;13:15-21.
156
160. |
Ritz E. Salt and hypertension. Nephrology. 2010; 15: 49– |
52.
161.Roca-Cusachs A., Aracil-Vilar J., Calvo-Gómez C. et al. Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther. 2008; 26: 91–100
162.Rocchini A.P, Key J., Bondie D. et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;
321:580–585.
163.Rodriguez-Iturbe B, Johnson RJ. The role of renal microvascular disease and interstitial inflammation in salt-sensitive hypertension. Hypertens Res. 2010;33(10):975-80.
164.Rodriguez-Iturbe B., Franco M., Johnson R.J. Impaired pressure natriuresis is associated with interstitial inflammation in salt-sensitive hypertension. Nephrol Hypertens. 2013;22(1):37-44.
165.Rodriguez-Iturbe B., Vaziri N.D. Salt-sensitive hypertension— update on novel findings. Nephrol. Dial. Transplant. 2007; 22 (4): 992-995.
166.Rodriguez-Iturbe В., Johnson R.J., Herrera-Acosta A.J. Tubulointerstitial damage and progression of renal failure. Kidney Int. 2009; 68 (99): 82–86.
167.Rosón M.I., Cavallero S., Della Penna S. et al. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats. Kidney International.2006; 70(8): 1439–1446.
168.Rostand S.G., Gretes J.C., Kirk K.A. et al. Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int. 1979;16:600– 611.
169.Ruilope L.M., van Veldhuisen D.J., Ritz E .et al. Kidney dysfunction: a sensitive predictor of cardiovascular risk. Am J Hypertens. 2001;14 ;6 (2):213-217.
157
170. |
Ruilope |
L.M.,van Veldhuisen D.J., Ritz E. et al. Renal |
function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol. 2001. 38 (7):
1782–7.
171.Sacks F.M., Svetkey L.P., Vollmer W.M. et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;
344:3–10.
172.Safar M.E., Thuilliez C., Richard V. et al. Pressure-independent contribution of sodium to large artery structure and function in hypertension. Cardiovasc Res. 2000; 46: 269–276.
173.Scientific Advisory Committee on Nutrition. Salt and Health, The Stationery Office, 2003: 24-27.
174.Shalitin N., Schlesinger H., Levy M.J. et al. Expression of procollagen C-proteinase enhancer in cultured rat heart fibroblasts: evidence for coregulation with type I collagen. J Cell Biochem. 2003; 90: 397–407.
175.Shin S.J., Lim C.Y., Rhee M.Y. et al. Characteristics of Sodium Sensitivity in Korean Populations. J Korean Med Sci. 2011; 26(8): 1061–1067.
176.Siegel G., Walter A., Kauschmann A. et al. Anionic biopolymers as blood flow sensors. Biosens Bioelectron. 1996; 11:281–294.
177.Simão A.N., Lozovoy M., Dichi I. The uric acid metabolism pathway as a therapeutic target in hyperuricemia related to metabolic syndrome. Expert Opinion on Therapeutic Targets. 2012; 16 (12): 1175-1187.
178.Skrabal F., Herholz H., Neumayr M. et al. Salt sensitivity is linked to enhanced sympathetic responsiveness and enhanced proximal tubular response. Hypertension. 1984; 6: 152–158.
179.Stamler J. The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr. 1997;66(5):1297.
180.Sterzel R.B., Luft F.C., Gao Y. et al. Renal disease and the development of hypertension in salt-sensitive Dahl rats. Kidney International. 1988;
33:1119-1129.
158
181. Strazzullo P., Galletti
of Sodium in Human Hypertension Short 2003; 41: 1000-1005.
F., Barba G. et al. Altered Renal Handling Review of the Evidence. Hypertension.
182.Tanaka T., Okamura T., Miura K. et. al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. Journal of Human Hypertension February. 2002; 16(2): 97-103.
183.The Intersalt Study. J Hum Hypertens 1989;3:179–330.
184.Tokimitsu I., Kato H., Wachi H. et al. Elastin synthesis is inhibited by angiotensin II but not by platelet-derived growth factor in arterial smooth muscle cells. Biochim Biophys Acta. 1994; 1207: 68–73.
185.Torffvit O., Melander O., Hultén U.L. Urinary Excretion Rate of Tamm-Horsfall Protein Is Related to Salt Intake in Humans. Nephron Physiol. 2004;97: 31–36.
186.Tozawa M. Iseki K. Iseki C. et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003; 41: 1341
–1345.
187.Udani S., Lazich I., Bakris G. L. Epidemiology of hypertensive kidney disease. Nature Reviews Nephrology. 2011; 7:11-21.
188.Van Paassen P., de Zeeuw D., Navis G. et al. Does the renin– angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension.1996; 27: 202–208.
189.Van Paassen P.,de Zeeuw D.,de Jong P.E. et al. Renin Inhibition Improves Pressure Natriuresis in Essential Hypertension. JASN. 2000;11(10):18131818.
190.Van Teeffelen J.W., Brands J., Stroes E.S. et al. Endothelial glycocalyx: sweet shield of blood vessels. Trends Cardiovasc Med. 2007; 17:101–105.
191.Vasan R.S., Larson M.G., Leip E.P. et al. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 17;358(9294):1682-6.
|
|
159 |
192. |
Veeraveedu |
P.T., Watanabe K., Ma M. et al. Comparative |
effects of torasemide and furosemide in rats with heart failure. Biochem Pharmacol. 2008; 75: 649–659.
193.Veeraveedu P.T., Watanabe K., Ma M. et al. Torasemide, a longacting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy. Eur J Pharmacol. 2008; 581: 121–131.
194.Visser F.W., Boonstra A.H., Lely A.T. et al. Renal Response to Angiotensin II is Blunted in Sodium-sensitive Normotensive Men. Am J Hypertens. 2008; 21 (3): 323-328.
195.Volpe M., Magri P., Rao M.A. et al. Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin-converting enzyme inhibition. Hypertension. 1997;30, 2 (1):168-176.
196.Wada T., Kodaira K., Fujishiro K. et al. Correlation of ultrasoundmeasured common carotid artery stiffness with pathological findings. Arterioscler Thromb. 1994;14:479–482.
197.Wargo K.A., Banta W.M. A Comprehensive Review of the Loop Diuretics: Should Furosemide Be First Line? Ann Pharmacother. 2009;43(11):183647.
198.Weber T., Auer J., O'Rourke M.F. et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions . Eur Heart J . 2005;26:2657–2663.
199.Weinbaum S., Tarbell J.M., Damiano E.R. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007; 9:121–16.
200.Weinberger M.H, Miller J.Z, Luft F.C. et al. Definitions and characteristics of sodium sensitivity and blood pressure resistance.Hypertension. 1986;8(2): 127 -134.
201.Weinberger M.H. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27,3 (2):481-90.
202.Whelton P.K., Appel L.J., Espeland M.A. et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized
160
controlled trial of nonpharmacologic interventions in the elderly (TONE).
TONE Collaborative Research Group. JAMA. 1998; 279(11):839–846.
203.Wilkinson I.B., MacCallum H., Flint L. et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000; 525:263–70.
204.Williams B., Lacy P.S., Thom S.M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006; 113: 1213–1225.
205.Williams G.H, Hollenberg N.K. Non-modulating hypertension. A subset of sodium-sensitive hypertension. Hypertension1991; 17 [1]: 81–85.
206.Wilson D.K., Sica D.A., Miller S.B. Ambulatory blood pressure nondipping status in salt-sensitive and salt-resistant black adolescents. Am J Hypertens
.1999; 12 (2): 159-165.
207.Yo Y., Nagano M., Moriguchi A. et al. Predominance of nocturnal sympathetic nervous activity in salt-sensitive normotensive subjects. Am J Hypertens.1996; 9: 726–731.
208.Zhao Q., Gu D., Hixson J.E et al. Collaborative Research GroupCirc Common Variants in Epithelial Sodium Channel Genes Contribute to Salt-Sensitivity of Blood Pressure: The GenSalt Study Cardiovasc Genet. 2011;1; 4(4): 375–380.
209.Zieman S.J.,Melenovsky V.,Kass D.A. Mechanisms, Pathophysiology, and Therapy of Arterial Stiffness Arterioscler Thromb Vasc Biol.2005;25(5):932-43.